In contrast, another clinical trial that enrolled 32 patients with pancreatic cancer showed the best response to MK-3475 and disease-free progression for 20 weeks after anti-PD-1 therapy [51]. This evidence concerns the gene PDCD1 and pancreatic neoplasm.